NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
复制标题
DOI:
10.6004/jnccn.2016.0087
复制
发表时间:
2016-07
期刊:
影响因子:
--
通讯作者:
Hughes M
中科院分区:
文献类型:
--
作者:
Ettinger DS;Wood DE;Akerley W;Bazhenova LA;Borghaei H;Camidge DR;Cheney RT;Chirieac LR;D'Amico TA;Dilling T;Dobelbower M;Govindan R;Hennon M;Horn L;Jahan TM;Komaki R;Lackner RP;Lanuti M;Lilenbaum R;Lin J;Loo BW Jr;Martins R;Otterson GA;Patel JD;Pisters KM;Reckamp K;Riely GJ;Schild SE;Shapiro TA;Sharma N;Swanson SJ;Stevenson J;Tauer K;Yang SC;Gregory K;Hughes M
These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.
登录
查看更多内容
影响因子:
50.5
作者:
Castagneto, B.;Botta, M.;Mencoboni, M.
通讯作者:
Mencoboni, M.
影响因子:
5.3
作者:
Boeluekbas, Servet;Manegold, Christian;Schirren, Joachim
通讯作者:
Schirren, Joachim
DOI:
10.1016/j.jtcvs.2007.10.054
发表时间:
2008-03-01
影响因子:
6
作者:
Flores, Raja M.;Pass, Harvey I.;Rusch, Valerie W.
通讯作者:
Rusch, Valerie W.
DOI:
10.1053/j.semtcvs.2013.07.002
发表时间:
2013-06-01
影响因子:
2.5
作者:
Friedberg, Joseph S.
通讯作者:
Friedberg, Joseph S.
影响因子:
20.4
作者:
Flores, Raja M.;Riedel, Elyn;Pass, Harvey I.
通讯作者:
Pass, Harvey I.